Sort by Expiration Date:
Filter:
Search

Archive

Sort by Expiration Date:
Filter:

Avoiding Delayed Diagnosis in Patients with Amyotrophic Lateral Sclerosis: What Can You Do to Improve the Patient Journey to Specialist Care?

This “situation room” activity allows learners to practice making clinical decisions in the management of patients with ALS. Learners will view simulated 2D interactions between patients and their physicians and use information from the patients’ electronic charts to decide the next best course of action. Topics covered in this activity include assessment of disease severity and quality of life, intensification of treatment, and recognizing adverse events.

Release Date: November 22, 2021
Expiration Date: November 22, 2022

Learn More & View Event »

Oncology Nurses Quality Improvement Series

This case-based online activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy, as well as, the treatment and management of patients with HER2-negative breast cancer.

Release Date: November 17, 2020
Expiration Date: November 17, 2021

Learn More & View Event »

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever- changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as the management of severe and critically ill patients, the treatment of pulmonary and extrapulmonary manifestations, and the impact of comorbidities on treatment.

Release Date: November 20, 2020
Expiration Date: November 20, 2021

Learn More & View Event »

An Animated Whiteboard Online View of Biological Agents for the Treatment of Systemic Lupus Erythematosus

This activity targets healthcare gaps related to the identification and understanding of potential therapeutic targets for treating systemic lupus erythematous (SLE), impacting SLE management and potential utilization of targeted treatment.

  • By addressing these gaps, you can assess whether your treatment approaches to SLE include considering the use of biologic agents in addition to corticosteroids and immunosuppressants, allowing modifications of treatment approaches to help close these gaps.
  • Expert discussion will guide you in identifying potential pathophysiologic targets, deciding whether treatment with biologic agents is indicated, and utilizing clinical trial data and algorithms to guide treatment approaches based on disease severity.
  • You will also be immersed in dynamic animations utilizing a whiteboard platform to memorably highlight key points related to disease pathophysiology as it relates to the role of interferons and biologic agents targeting the interferon alpha receptor.

Release Date: December 17, 2020
Expiration Date: December 17, 2021

Learn More & View Event »

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

Release Date: December 23, 2020
Expiration Date: December 23, 2021

Learn More & View Event »

Reducing the Burden of Atrial Fibrillation: A Whiteboard Animated Tour of Antiarrhythmic Drugs for Cardiologists

This online activity targets healthcare gaps related to the treatment and management of atrial fibrillation (AF), impacting outcomes through guidelines and best practices, appropriate antiarrhythmic use and shared decision-making.

  • By addressing these gaps, you can assess whether your approach to AF management through utilization of current treatment guidelines and strategies for shared decision making – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for antiarrhythmic intervention, utilizing clinical trial and real-world data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a whiteboard platform to memorably highlight key points related to antiarrhythmic mechanisms of action and consequences related to interactions with other cardiovascular agents.

Release Date: January 4, 2021
Expiration Date: January 4, 2022

Learn More & View Event »

COVID-19 Frontline: Emerging Monoclonal Antibody Therapies and Vaccines for COVID-19: How They Work and When to Use Them

This COVID-19 FRONTLINE Whiteboard series will explore the role of emerging monoclonal antibody therapies and vaccines in managing the COVID-19 pandemic. Each module will focus on clinical trial data and aid clinicians in identifying patients who would benefit from therapy.

In this module, we will compare the mechanism of action of monoclonal and polyclonal antibodies and evaluate clinical trial evidence on the efficacy and safety of these therapies for the management of COVID-19.

Release Date: February 2, 2021
Expiration Date: February 2, 2022

Learn More & View Event »

COVID-19 Frontline: Emerging Monoclonal Antibody Therapies and Vaccines for COVID-19: How They Work and When to Use Them

This COVID-19 FRONTLINE Whiteboard series will explore the role of emerging monoclonal antibody therapies and vaccines in managing the COVID-19 pandemic. Each module will focus on clinical trial data and aid clinicians in identifying patients who would benefit from therapy.

In this module, we will review the mechanism of action of monoclonal antibody therapies and vaccines for the prevention and treatment of COVID-19, and assess the efficacy and safety of these emerging therapies.

Release Date: February 2, 2021
Expiration Date: February 2, 2022

Learn More & View Event »

COVID-19 Frontline: Emerging Monoclonal Antibody Therapies and Vaccines for COVID-19: How They Work and When to Use Them

This COVID-19 FRONTLINE Whiteboard series will explore the role of emerging monoclonal antibody therapies and vaccines in managing the COVID-19 pandemic. Each module will focus on clinical trial data and aid clinicians in identifying patients who would benefit from therapy.

In this module, we will investigate the risk of therapy failure due to SARS-CoV-2 mutation with single and dual monoclonal antibody therapies.

Release Date: February 2, 2021
Expiration Date: February 2, 2022

Learn More & View Event »

Accurate Diagnosis and Effective Management of Children with Growth Hormone Deficiency: What Can You Do to Improve Patient Outcomes in Your Clinical Practice?

This game-based activity highlights how to diagnose, treat, and/or manage patients with chronic spontaneous urticaria in their patients. The goals of the program are to enhance the clinician’s ability to use clinical findings and molecular biomarkers to identify disease severity and predict response to treatment; design treatment regimens for patients with CSU who fail to respond to therapy; and select appropriate therapeutic options based on evaluation of emerging clinical trial data.

Learn More & View Event »

Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention

This online activity targets healthcare gaps correlated with early intervention in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) without center-involved macular edema, which can have a profound impact on vision-related quality of life.

Release Date: February 19, 2021
Expiration Date: February 19, 2022

Learn More & View Event »

A Whiteboard View of the New Era in Alopecia Areata: The Role of JAK Inhibitors

This case-based activity targets healthcare gaps related to the underlying autoimmune causes of alopecia areata (AA) and targeted treatment approaches, which can have a profound impact on health-related quality of life through burden of disease and associated comorbidities. This content was co-created by Dr. Brett King (New Haven, CT) and Dr. Rodney Sinclair (Melbourne, Australia).

  • By addressing these gaps, you can assess whether your approach to AA management through utilization of immune-related targeted treatment approaches and comorbidity assessment – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for immune-targeted treatment of alopecia with JAK inhibitors, as well as assessment and management strategies for associated comorbidities.
  • You will also be immersed in dynamic animations utilizing a whiteboard platform to memorably highlight key points related to immune pathways in the development of alopecia areata and patient counseling techniques for tailored disease and comorbidity management.

Release Date: February 25, 2021
Expiration Date: February 25, 2022

Learn More & View Event »

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

The COVID-19 FRONTLINE TeleECHO program provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. This recorded TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19.

Release Date: March 4, 2021
Expiration Date: March 4, 2022

Learn More & View Event »

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Diabetic Retinopathy
Immersive Simulation Experience

The diabetic retinopathy (DR) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in DR management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of retinopathy severity, intensification of treatment, as well as the recognition and management of adverse events.

Release Date: March 18, 2021
Expiration Date: March 18, 2022

Learn More & View Event »

The RELIEF Initiative
Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic

This situation room activity allows learners to practice making clinical decisions in the management of patients with psoriatic arthritis. Learners will view a simulated interaction between a patient and their physician and use information from the patient’s electronic chart to decide the next best course of action. Topics covered in this activity include assessment of disease severity, treatment selection, and managing patients with SARS-CoV-2 infection or exposure.

Release Date: March 18, 2021
Expiration Date: March 18, 2022

Learn More & View Event »

Managing Toxicities Associated with HER2-Targeted Therapy: Focus on Pulmonary Events

This activity will allow clinicians to recognize the symptoms of interstitial lung disease, a potentially serious pulmonary toxicity associated with several HER2-targeted therapies for the treatment of cancer. Learners will be able to recognize the signs and symptoms of pulmonary toxicity associated with systemic cancer therapy including interstitial lung disease and pneumonitis.

Release Date: March 30, 2021
Expiration Date: March 30, 2022

Learn More & View Event »

ECHO Series: Timely Recognition, Management, and Referral of Axial Spondyloarthritis

The AxSpA TeleECHO enduring will explore strategies to promptly recognize, diagnose, and manage patients with axial spondyloarthritis (AxSpA). This program provides an interactive platform that includes didactic programming in addition to case-based discussion on the selection of therapeutic options and the management of patients with AxSpA.

Release Date: March 30, 2021
Expiration Date: March 30, 2022

Learn More & View Event »

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration
Immersive Simulation Experience

The Age-related Macular Degeneration (AMD) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in AMD management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of AMD classification, risk factor modification, interventions based on AMD classification, as well as the recognition and management of treatment-related adverse events.

Release Date: April 2, 2021
Expiration Date: April 2, 2022

Learn More & View Event »

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Retinal Vein Occlusion
Immersive Simulation Experience

The Retinal Vein Occlusion (RVO) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in RVO management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of RVO classification, risk factor modification, interventions based on RVO classification, as well as the recognition and management of treatment-related adverse events.

Release Date: April 23, 2021
Expiration Date: April 23, 2022

Learn More & View Event »

A Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

The COVID-19 FRONTLINE TeleECHO session provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. This recording features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Release Date: May 3, 2021
Expiration Date: May 3, 2022

Learn More & View Event »

Please note that the program was recorded before nivolumab was approved on August 19, 2021, for the adjuvant treatment of people with urothelial carcinoma who are at high risk of recurrence after radical resection. The approval is supported by results of a randomized, double-blind, placebo-controlled trial showing a statistically significant improvement in disease free survival observed in both the intent-to-treat patient cohort and in those whose tumors express PD-L1 ≥1%. The results of the clinical trial supporting this approval also led to the conversion of nivolumab’s accelerated approval to regular approval in advanced/metastatic UC.

Immunotherapy of Bladder Cancer: Integrating New Biomarkers and Treatment Guidelines into Clinical Practice

This activity will cover the treatment and management of patients with bladder cancer.

Release Date: May 7, 2021
Expiration Date: May 7, 2022

Learn More & View Event »